Scientific program ADDRMONLINE 2021

11.00 - 11.05 - Plenary opening

11.05 - 11.35 - Meet the Expert

11.05 - 11.35 Meet the Expert 1: Mechanistic insights of SGLT2 inhibitors
Prof. dr. Ele Ferrannini, University of Pisa

11.35 - 12.35 - You can choose between 3 sessions

11.35 – 11.47 Sex disparities in the quality of medication treatment among patients with type 2 diabetes
M Ambroz (Groningen)
11.47 – 11.59 Effectiveness of a stepped-care approach versus immediate continuous glucose monitoring-based technologies in hypoglycaemia-prone patients with type 1 diabetes (ECSPECT-HYPO)
E. Serné (Amsterdam)
11.59 – 12.11 Cost-effectiveness and cost-utility of foot temperature monitoring for preventing diabetic foot ulcer recurrence: a randomized controlled trial
J.J. van Netten (Amsterdam)
12.11 – 12.23 Androgens and Development of Post-Transplantation Diabetes Mellitus in Male Kidney Transplant Recipients: A post-hoc analysis of a prospective study
S.P. Stam (Groningen)
11.35 – 11.47 Single-cell RNA sequencing of human pancreatic islets reveals a role of pancreatic duct cells as mediator of the inflammation during the early stage of T1D
A.M.G. Munoz Garcia (Leiden)
11.47 – 11.59 Methylprednisolone prevents insulin dysfunction and cell death in human islets exposed to proinflammatory cytokines
M. Paz Barba (Leiden)
11.59 – 12.11 Markers of residual beta-cell function are associated with more time in euglycaemic range in type 1 diabetes
C.M. Fuhri Snethlage (Amsterdam)
12.11 – 12.23 The increase of the iron-transporting glycoprotein ceruloplasmin upon inflammatory stress is specific for the alpha cell population
F.W.J. Boot (Leiden)
12.23 – 12.35 Immunoproteasome expression correlates with beta cell immunogenicity and accelerates processing of DRiP epitopes
S.Thomaidou (Leiden)
12.23 – 12.35 Impact of the COVID-19 lockdown on behaviour, stress, anxiety and glycaemic control in patients with beta cell transplantation for type 1 diabetes
C.P. Landstra (Leiden)
11.35 – 11.47 Diabetes complications are associated with an altered inflammatory state in type 1 diabetes: a proteomics approach
M. Ajie (Radboudumc)
11.47 – 11.59 Supplementation of methylglyoxal in drinking water does not affect the cerebral microvasculature and cognitive function in non-diabetic mice
E. Berends (Maastricht)
11.59 – 12.11 ECG abnormalities and major adverse cardiac events in people with type 2 diabetes: The Hoorn Diabetes Care System cohort
Peter P. Harms (Amsterdam)
12.11 – 12.23 The association of serum magnesium with cardiovascular complications in type 1 and 2 diabetes
L. Oost, (Nijmegen)
12.23 – 12.35 Association between de novo lipogenesis susceptibility genes and coronary artery disease
P.I.H.G. Simons (Maastricht)

12.35 - 13.05 - Lunch break

13.05 - 14.05 - You can choose between 3 sessions

13.05 – 13.17 Effects of dapagliflozin and combination therapy with exenatide on food-cue induced brain activation in patients with type 2 diabetes: a randomized controlled trial
C.C. van Ruiten (Amsterdam)
13.17 – 13.29 Kidney Function Measures and Cardiovascular Outcomes in People with Diabetes: the Hoorn Diabetes Care System cohort
E. Dal Canto (Amsterdam)
13.29 – 13.41 Treatment with Semaglutide 2.4 mg Leads to Improvements in Cardiometabolic Risk Factors in the STEP 1 Trial
D. Smit (Tilburg)
13.41 – 13.53 An integrated e-health support of shared decision making and self-management (POWER2DM) for patients with diabetes mellitus and their healthcare professionals
M.M. Ruissen (Leiden)
13.05 – 13.17 Persistent pro-inflammatory effects of a single hypoglycaemic event in humans with and without type 2 diabetes
J.I.P. van Heck (Nijmegen)
13.17 – 13.29 Habitual intake of dietary dicarbonyls is associated with higher insulin sensitivity and lower odds of type 2 diabetes: The Maastricht Study
K. Maasen (Maastricht)
13.29 – 13.41 Gestational Diabetes Mellitus perturbes offspring glucose excursion at young adult age
K. Hribar (Groningen)
13.41 – 13.53 Novel biomarkers for glycaemic deterioration in type 2 diabetes: an IMI RHAPSODY study
R.C. Slieker (Leiden)
13.53 – 14.05 Development of a new Phosphorus Magnetic Resonance Technique to detect NAD-metabolites in skeletal muscle
J. Mevenkamp (Maastricht)
13.05 – 13.17 Three weeks of time restricted eating improves fasting glucose in type 2 diabetes patients but does neither increase nocturnal fat oxidation nor insulin sensitivity
C. Andriessen, (Maastricht)
13.17 – 13.29 Effect of lowering branched-chain amino acid levels in patients with type 2 diabetes using sodium-phenylbutyrate
E. Phielix (Maastricht)
13.29 – 13.41 Context of physical activity matters for risk of type 2 diabetes
J.H.P.M. van der Velde (Leiden)
13.41 – 13.53 Cadmium, Active Smoking and Renal Function Deterioration in Patients with Type 2 Diabetes
M.M. Oosterwijk (Almelo)

14.05 - 15.05 - You can choose between 3 sessions

14.05 – 14.17 Seven weeks of oral histidine supplementation improves glycemic control in type 2 diabetes patients
M.V. Warmbrunn (Amsterdam)
14.17 – 14.29 Sex disparities in treatment transitions after metformin initiation among patients with type 2 diabetes
M.P Oktora (Groningen)
14.29 – 14.41 Sustaind improvement of glycaemic outcomes in people with type 1 diabetes one year into the COVID-19 pandemic
N.Ali (Nijmegen)
14.41 – 14.53 Older age, polypharmacy, and low systolic blood pressure are associated with more hypotension-related adverse events in patients with type 2 diabetes treated with antihypertensives
M. Ambroz (Groningen)
14.05 – 14.17 Associations among treatment targets, social determinants of health and health care utilisation in Dutch people with type 2 diabetes and mental disorders : results of a linked observational dataset
E.A. Nieuwenhuijse (Den Haag)
14.17 – 14.29 In patients with obesity, higher levels of psychological stress are associated with lower levels of the insulin-sensitizer FGF21
S. Kuckuck and R. Lengton (Rotterdam)
14.29 – 14.41 “I am my own doctor”: a qualitative study of the perspectives and decision-making process of Muslims with diabetes on Ramadan fasting
S. Bouchareb, (Amsterdam)
14.41 – 14.53 Momentary Assessment of Type 1 Diabetes patient’s Experiences in Glucose Variability and Mood in Real life (MERITS): First findings
M. de Wit (Amsterdam)
14.05 – 14.17 Distinct associations of plasma methionine and cysteine with fat depots: CODAM and The Maastricht Study
E.C. Tore (Maastricht)
14.17 – 14.29 A novel in vitro model of metabolically-activated human macrophages for studying adipocyte-macrophage cross-talk during obesity
J.M. Lambooij (Leiden)
14.29 – 14.41 Pregestational hyperglycemia associates with lower offspring survival rates and accelerates maternal NAFLD development in mouse model for gestational diabetes
A.J.C. Tol (Groningen)
14.41 – 14.53 Acute vagal nerve stimulation enhances hepatic glucose uptake in anaesthetized rats
C.W. Hoornenborg (Groningen)
14.53 – 15.05 Diet-induced Weight Loss Lowers Plasma Complement C3 via Reduction of Visceral Adipose Tissue: a Randomized Controlled Trial in Abdominally Obese Men
S. Jin (Maastricht)

15.05 - 15.35 - Award Session

15.05 – 15.35 Prof. dr. J. Terpstra Award
Prof. dr. Bastiaan de Galan
Dr. F. Gerritzen Prijs
Dr. Esther Phielix

15.35 - 16.05 - Meet the Expert

15.35 - 16.05 Intestinal bacteria for type 1 diabetes
Prof. dr. Max Nieuwdorp, Amsterdam UMC

16.05 - 17.00 - Closing and best meeting abstracts

16.05 – 17.00 A single hypoglycaemic event drives a prolonged inflammatory response in individuals with and without type 1 or type 2 diabetes
C.E.M. Verhulst (Nijmegen)
A common variant in the ketohexokinase gene is associated with fructosuria and cardiometabolic outcomes
A.M Buziau (Maastricht)
ER-mitochondria cross-talk during stress activates innate immune response in beta-cell and contributes to immune cell recruitment
S. Vig (Leiden)
Towards a GMP-Compliant Protocol for the Differentiation of Human Pluripotent Stem Cells to Beta-like Cells for the Treatment of Type 1 Diabetes
B. Rajaei (Leiden)

17.00 - Closing


Logo Novo Nordisk
Logo Boehringer Ingelheim


Logo Sanofi
logo Lilly
Logo AstraZeneca